Pharma & Biotech Insights, Interviews & Features
Biotechnology
14 November 2024 14 November 2024
Today's issue
Refine Search
Biotechnology
This week, we discuss a novel AI-driven approach to drug development, and its potential to transform the treatment of cancer and autoimmune diseases. 14 November 2024
Biotechnology
An Expert View from Cumulus Oncology about its innovative business model, which is all about improving the efficiency of drug R&D. 11 November 2024
Generics
Indian drugmaker Aurobindo Pharma has taken on the might of China in terms of Penicillin G pricing, and is doing so by leveraging a fully integrated production process at its new plant. Anticipating the price erosion of Penicillin G, the company has put up an integrated plant from scratch. 10 November 2024
Pharmaceutical
Life science investors can be divided into two groups: those who bought Novo Nordisk stock before GLP-1s hit the big time, and those who wish they had. 10 November 2024
Generics
Indian markets are abuzz with a singular refrain. Donald Trump's Presidency of the United States is set to open new opportunities for India, especially in the pharmaceutical sector. 8 November 2024
Biotechnology
According to UNICEF's State of the World's Children 2023 report, in Latin America
and the Caribbean, 6.8 million children did not benefit from vaccination during the
time of the pandemic and in the following two years, progress has not been as
expected either. 7 November 2024
Biotechnology
As India's bioeconomy soars to a remarkable valuation of $151 billion, the government's Biotechnology Industry Research Assistance Council (BIRAC) has underscored the critical need for innovation and private sector investment to unlock further growth. 21 October 2024
Pharmaceutical
An Expert View from Nick Petschek, Managing Director EMEA, Kotter International. 18 October 2024
Biotechnology
Where once the state of play in the cell and gene therapy space was mostly limited to hope and hype around what might be to come, this is increasingly being replaced by action, on-market therapies and genuine expectation of reaching patients—provided companies can avoid some of the sector’s notorious pitfalls. 16 October 2024
Biotechnology
Antibody-drug conjugates (ADCs) represent a transformative class of cancer therapy that combine the targeting ability of antibodies with the cell-killing potential of cytotoxic drugs. 15 October 2024
Biotechnology
At last month’s European Academy of Dermatology and Venereology (EADV) congress in Amsterdam, Novartis presented new early and long-term Phase III data for remibrutinib in chronic spontaneous urticaria (CSU). 14 October 2024
Biotechnology
India's new Biotechnology Research Innovation and Entrepreneurship Development (Bio-RIDE) scheme is a significant step towards consolidating and advancing the country's biotechnology initiative. 7 October 2024
Pharmaceutical
F2G’s September $100m funding round provides the company with crucial funds to
renavigate approval of its lead drug, olorofim. The substantial financing also
highlights the paucity of novel antifungal products in the clinic. 3 October 2024
Pharmaceutical
Timing can be crucial in biotech, and any company that can help optimize radiopharmaceuticals to fight cancer is likely to a hot property right now, given the recent popularity of the field among investors and drugmakers. 2 October 2024
Pharmaceutical
As stakeholders in the pharmaceutical industry, we all have a responsibility to ensure life-saving treatments promptly and safely reach patients regardless of where they live. To this end, by integrating early access programs and other less conventional strategies into a company’s business model for drug distribution, patients who are suffering from life-threatening conditions can gain access to needed treatments in regions where there is a lack of drug accessibility, while at the same time offering benefits to pharmaceutical companies. 2 October 2024
Pharmaceutical
The Russian government has finalized the rules for granting preference to domestic drugs in public procurements, which will come into force in 2025. 1 October 2024
Pharmaceutical
A Feature on M&A, licensing and partnerships hotting up in inflammatory diseases as new targets present new opportunities for future growth. 30 September 2024
Pharmaceutical
India is set to complete 50 new greenfield pharma manufacturing plants in the next two years under its Production-linked Incentive (PLI) scheme for pharma and medical devices. 30 September 2024
Generics
The number of clinical trials of new drugs in Russia is steadily declining, which could be mainly related with the overall reduction of investment activities in the local pharmaceutical market, reports The Pharma Letter’s local correspondent. 30 September 2024
Pharmaceutical
Scarcely anything unites lawmakers in America these days, but the ostensible iniquities of Big Pharma could be a rare exception. 22 September 2024
Pharmaceutical
Twenty-seven years ago last January, a letter in the New England Journal of Medicine concluded that: “despite widespread use of narcotic drugs in hospitals, the development of addiction is rare in medical patients with no history of addiction.” 12 July 2017
Biotechnology
US biotech major Biogen has brought in a woman with a background in both biopharma and the public sector as its new vice president of governmental affairs. 11 July 2017
Biosimilars
Serving the twin purposes of creating a globally competitive biopharmaceutical industry that addresses India's major concerns around barriers to affordable healthcare, India's Department of Biotechnology (DBT) is set to roll out biosimilar drugs for diseases such as cancer, diabetes and rheumatoid arthritis, reports The Pharma Letter’s India correspondent. 11 July 2017
Biotechnology
US biotech major Biogen has received approval from Japan’s Ministry of Health, Labor Welfare (MHLW) for its orphan drug Spinraza (nusinersen) to treat infantile-onset spinal muscular atrophy (SMA), reports The Pharma Letter’s local correspondent Wang Fangqing. 10 July 2017
Pharmaceutical
Bosnalijek, Bosnia and Herzegovina’s largest drugmaker, is considering building a plant for the production of its drugs in the Russian city of Kaluga, according to the company, reports The Pharma Letter’s local correspondent. 7 July 2017
Biotechnology
Daniel O’Connor has resigned as chief executive of US biotech Advaxis. 7 July 2017
Generics
Indian generic drugmaker Hetero Labs has announced plans to build a plant for the production of drugs against cancer and AIDS in Russia. 7 July 2017
Biotechnology
Ferring Pharmaceuticals says that Lars Peter Brunse has been appointed executive vice president and chief production officer, and made a member of the Ferring executive board, effective immediately. 5 July 2017
Generics
Following swiftly on last week’s shareholders rejected takeover bid for Stada Arzneimittel (SAZ: Xetra) by private equity firms Bain Capital and Cinven, two of the companies top executives have proffered their resignations. 4 July 2017
Biotechnology
Biopharmaceutical research draws from a diffuse range of highly specialized technologies, and the traditional wisdom is that pharmaceutical firms, even very large companies, have little choice but to collaborate with others if they are to succeed. 4 July 2017
Pharmaceutical
The growing number of clinical trials and increasing complexity across the clinical lifecycle are putting pressure on life sciences organizations to improve study quality and execution, writes Rik Van Mol, vice president of R&D strategy, Europe, Veeva Systems, in an Expert View piece. 4 July 2017
Pharmaceutical
Dr Nicola Davies looks at how real world evidence carries ever greater importance in an industry where often regulatory approval alone is no longer enough. 4 July 2017
Biosimilars
By Dr Nicola Davies
As many first-generation biologics reach the end of their patent life, biosimilars have the potential to bring about much-needed cost savings for the US healthcare system by increasing competition and driving down prices. However, writes Dr Nicola Davies in her regular exclusive FDA Blog for The Pharma Letter, biosimilar developers must overcome the US Food and Drug Administration’s regulatory requirements to gain access to the world’s largest pharmaceutical market. 3 July 2017
Biotechnology
Belgian biotech firm iTeos Therapeutics has appointed a new vice president of corporate development, Mohamed Ragab. 29 June 2017
Biotechnology
American biotech company Biogen has appointed a new senior VP of corporate affairs, Catherine Steele. 28 June 2017
Pharmaceutical
As a result of the recent decision of the Russian Ministry of Health to allow the use of combined vaccines to vaccinate children at risk, French pharma major Sanofi and Russia’s Nanolek could increase their sales in Russia this year. 27 June 2017
Pharmaceutical
Swiss pharma giant Roche (ROG: SIX) has signed an agreement on investing 5 billion roubles ($84 million) on conducting R&D activities and the development of new drugs in Russia, reports The Pharma Letter’s local correspondent. 27 June 2017
Biotechnology
Dragonfly Therapeutics has appointed Nicolai Wagtmann as its chief scientific officer (CSO). 27 June 2017
Pharmaceutical
Even as Indian drug firms continue to reel under plans by the Trump administration in the USA to repeal and replace some parts of The Patient Protection and Affordable Care Act, popularly known as Obamacare, four prominent US lawmakers have outlined a number of concerns, including inadequate intellectual property rights protection, reports The Pharma Letter’s India correspondent. 26 June 2017
Pharmaceutical
Todd Greenwood, director of digital Strategy at digital health specialists Medullan, provides an expert view on the value of real-world evidence and patient support in the successful implementation of a value-based approach to healthcare. 26 June 2017
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze